Accessibility Menu
China Sxt Pharmaceuticals logo

China Sxt Pharmaceuticals(NASDAQ) SXTC

Market Cap$1.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-100%
1 Month-97%
$0.08
+21.68%
+0.01Today
After hours$0.07-$0.01 (-6.78%)
China Sxt Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.082026-08-03
China Sxt Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.17%USD 0.072026-07-27
1 month-96.86%USD 2.452026-07-02
3 month-95.7%USD 1.792026-05-05
Year to date-99.97%USD 240.002025-12-31
1 year-99.97%USD 255.002025-08-01
3 year-100%USD 6,270.002023-08-04
5 year-100%USD 720,000.002021-08-04
Since inception-100%USD 13,774,898.012019-01-04

China Sxt Pharmaceuticals Financials at a Glance

Market Cap

$1.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.54M

Net Income (TTM)

-$7.37M

EPS (TTM)

-$8.06

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

2.39 (High)

Price

$0.08

Volume

430,396,392

Open

$0.07

Previous Close

$0.08

Daily Range

$0.07 - $0.10

52-Week Range

$0.05 - $1,046.99

Estimated Earnings Date

Jul 30, 2026

SXTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About China Sxt Pharmaceuticals

China SXT Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers a range of TCMP products and raw medicinal materials, serving various healthcare sectors.

Products and Services
  • Advanced, fine, and regular TCMP products
  • Raw medicinal materials including SanQiFen and HongQi
  • Products marketed under Suxuantang, Hui Chun Tang, and Tong Ren Tang brands
Growth Outlook
  • Significant market potential in traditional Chinese medicine sector
  • Expansion plans targeting pharmaceutical companies and hospitals
  • Increased demand for natural and holistic health solutions
Financial Highlights
  • Recent quarterly revenue of 1,198,476, showing growth potential
  • Cash and cash equivalents of 28,176,233, indicating strong liquidity
  • Current ratio of 7.93, reflecting solid short-term financial health
China SXT Pharmaceuticals, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, focusing on traditional Chinese medicine. The company has established a diverse product line that caters to various healthcare providers, including hospitals and pharmacies. Recent financial data indicates a revenue of 1,198,476 for the latest quarter, showcasing the company's ability to generate income despite challenges. The cash position remains robust, with over 28 million in cash and cash equivalents, providing a cushion for operational needs and potential investments. The current ratio of 7.93 suggests that the company is well-positioned to meet its short-term liabilities, enhancing its financial stability. Overall, China SXT Pharmaceuticals presents an intriguing opportunity for investors interested in the growing field of traditional medicine and healthcare solutions.
AI Generated • Jul 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

56

CEO

Sze Beng Lim; Feng Zhou

Website

www.sxtchina.com

Headquarters

Taizhou, JS 225300, CN

SXTC Financials

Key Financial Metrics (TTM)

Gross Margin

44.37%

Operating Margin

-336.53%

Net Income Margin

-290.71%

Return on Equity

-31.02%

Return on Capital

-23.11%

Return on Assets

-21.22%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

32.22M

Volume

430.40M

Avg. Volume

23.57M

Financials (TTM)

Gross Profit

$1.13M

Operating Income

-$8.54M

EBITDA

-$8.37M

Operating Cash Flow

-$6.14M

Capital Expenditure

$988.15K

Free Cash Flow

-$5.15M

Cash & ST Invst.

$28.18M

Total Debt

$1.12M

China Sxt Pharmaceuticals Performance Analysis

China Sxt Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 1,971,679-24.2%
20242024-03-31USD 1,928,497-2.2%
20252025-03-31USD 1,740,907-9.7%
20262026-03-31USD 1,138,052-34.6%
China Sxt Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31N/A
Q22025-09-30N/A
Q32025-12-31-59.2%
Q42026-03-31368.6%
China Sxt Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -26,675.69-99.2%
20242024-03-31USD -4,286.54-83.9%
20252025-03-31USD -348.17-91.9%
20262026-03-31USD -9.13-97.4%
China Sxt Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-03-31N/A
Q22025-09-30N/A
Q32025-12-31101.7%
Q42026-03-3121.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$1.20M

+163.0%

Gross Profit

$833.97K

+616.9%

Gross Margin

69.59%

N/A

Market Cap

$1.99MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$35.58K

N/A

Employees

56

N/A

Net Income

$163.72K

+113.1%

EBITDA

-$672.89K

+33.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$28.18M

+54.5%

Total Debt

$1.12M

+13.9%

Accounts Receivable

$3.23M

+148.4%

Inventory

$2.96M

+161.8%

Long Term Debt

$697.83K

+229.7%

Short Term Debt

$423.15K

-45.2%

Return on Assets

-21.22%

N/A

Return on Invested Capital

-28.07%

N/A

Free Cash Flow

-$2.26M

-214.2%

Operating Cash Flow

-$2.26M

-214.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IXHLIncannex Healthcare Limited
$2.93-0.34%
SAVACassava Sciences, Inc.
$1.32+2.33%
ATLNAtlantic International Corp.
$0.90+0.00%
MISTMilestone Pharmaceuticals Inc.
$1.12+0.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About SXTC

What is the current price of China Sxt Pharmaceuticals?

China Sxt Pharmaceuticals is trading at $0.08 per share.

What is the 52-week range for China Sxt Pharmaceuticals?

Over the past 52 weeks, China Sxt Pharmaceuticals has traded between $0.05 and $1,046.99.

How much debt does China Sxt Pharmaceuticals have?

As of the most recent reporting period, China Sxt Pharmaceuticals reported total debt of $1.12M.

How much cash does China Sxt Pharmaceuticals have on hand?

China Sxt Pharmaceuticals reported $28.18M in cash and cash equivalents in its most recent financial results.

What is China Sxt Pharmaceuticals’s dividend yield?

China Sxt Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services